Key Drivers
- Strong Cash Flow
- Low Leverage
- Margin Compression
AIAI Summary
REGN now looks like a resilient, cash-rich mature biotech rather than a broad pipeline story, and after the fianlimab setback the stock's upside depends on execution from a few selective drivers like cemdisiran, Dupixent/EYLEA expansion, and the radiopharma collaboration while downside remains cushioned by strong free cash flow and liquidity.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •Low Leverage
- •Margin Compression
REGN remains a high-quality, cash-generative business with strong liquidity and low leverage, but recent margin compression and a fair-to-full valuation suggest limited upside unless execution improves.
Price Behavior
Key Price Behavior Insights:
- •Breakout Momentum
- •Support Retest
- •Volatility Risk
REGN rebounded strongly over the last month, breaking above $635–$639 on improving momentum, but the move remains volatile and must hold $620–$625 support to confirm the trend.
Sharp drop from $635.45 to $601.65 in early
Sentiment & News
Key News Insights:
- •Growth drivers
- •FDA/EMA progress
- •Legal scrutiny
Regeneron's recent news is broadly constructive, driven by strong product growth, regulatory wins for cemdisiran, and manufacturing-approval momentum, but partially offset by shareholder legal investigations.
The news flow is net positive for REGN, supporting momentum and catalyst visibility, though ongoing fraud-related investigations could create headline risk
Similar Companies in Healthcare
Other companies in the same sector with AI ratings